Hedge Fund Manager Tom Russo’s Top Stock Picks for 2013

The fund slightly increased the size of its position in Mastercard Inc (NYSE:MA) to a total of about 890,000 shares. Analysts expect considerable earnings growth at Mastercard in 2013, with the result being a current-year P/E multiple of 20. However, we think that credit card companies such as Discover Financial Services (NYSE:DFS) or Capital One (NYSE:COF) might be better values given their considerably lower earnings multiples. Renaissance Technologies, founded by billionaire Jim Simons, was another fund which reported a large stake in Mastercard for Q3 2012 (find Renaissance’s favorite stocks).

Gardner Russo & Gardner didn’t only invest in Berkshire, they also invested separately in one of Buffett’s top picks: Wells Fargo & Company (NYSE:WFC), reporting a position of almost 12 million shares. Wells Fargo is seen as a relatively stable bank and so it trades at a premium to book value with a P/B ratio of 1.3. However, the company has been very strong in terms of monetizing its assets: the same valuation is only 10 times its trailing earnings, and in the fourth quarter of 2012 earnings increased 24% from a year earlier. Wells Fargo was one of the most popular stocks among hedge funds in the third quarter of last year (see the full top ten list).

Russo and his team owned about 4 million shares of Anheuser-Busch InBev NV (NYSE:BUD), making the brewer another of their favorite stocks. Lee Ainslie’s Maverick Capital had been buying the stock between July and September. Anheuser-Busch is up 49% in the last year, which has brought it to a multiple of 18 times expected earnings for 2013. In Q3 2012 net income was up 16% from its levels in the same period in 2011. It might be worth looking into the sources of that growth- sales growth was not nearly as high- to see if the company can sustain that performance.

Disclosure: I own no shares in any stocks mentioned in this article.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!